Syneron Medical Ltd. (NASDAQ: ELOS) has signed a definitive agreement to acquire substantially all the assets of TransPharma Medical Ltd. TransPharma Medical, a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transdermal drug delivery technology, has developed a transdermal drug delivery technology based on RF-MicroChannels™ that create microscopic channels across the skin. The company's Viador system is a handheld device with an RF-needle array with CE Mark approval for use in transdermal delivery of biologic drug-products via a system-specific skin patch. The system may be commercialized for both in-office and at-home applications. Under terms of the agreement, Syneron will acquire substantially all the assets of TransPharma, including its patent portfolio, for approximately $3.6 million in cash. The acquisition is subject to customary closing conditions.